Abstract
Polymyxin B (PB) plus meropenem (MER) or rifampin (RIF) was tested by Etest® method and time-kill assay (TKA) against 14 genetically unique clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. PB + MER: Etest, 43% synergy; TKA, 64% synergy. Concordance between methods was 79%. For PB + RIF: Etest, 21% synergy; TKA, 100% synergy. Concordance between methods was 21%.
Copyright © 2011 Elsevier Inc. All rights reserved.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Bacterial Proteins / metabolism*
-
Drug Synergism*
-
Humans
-
Klebsiella Infections / microbiology
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / enzymology
-
Klebsiella pneumoniae / isolation & purification
-
Meropenem
-
Microbial Sensitivity Tests
-
Microbial Viability / drug effects
-
Polymyxin B / pharmacology*
-
Rifampin / pharmacology*
-
Thienamycins / pharmacology*
-
Time Factors
-
beta-Lactamases / metabolism*
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Thienamycins
-
beta-Lactamases
-
carbapenemase
-
Meropenem
-
Polymyxin B
-
Rifampin